The investigators test the renal and cardiovascular protective effects dextromethorphan and silymarin on patients with the proteinuric chronic kidney diseases, who enrolled in our clinical trial, had progressing kidney diseases and merit aggressive anti-inflammatory therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
National Cheng-Kung University Hospital
Taian, Taiwan, Taiwan
change of eGFR
Use MDRD-simplified equation
Time frame: 4 months
Change of Urine TP/Cr
Time frame: 4 months
Change of serum hsCRP
Time frame: 4 months
Change of urine TGF-beta/Cr level
fibrotic marker of kidney
Time frame: 4 months
Endothelial function
by Flow-mediated dilatation mesured by Crdiovascular ultrasound
Time frame: 4 months
Leukocyte ROCK activity
Measure leukocyte Ro kinase activity by western blotting This is an indicator of cardiovascular function
Time frame: 4 months
Blood MDA level
Indicator of oxidative stress
Time frame: 4 months
Blood TGF-beta
By Elisa
Time frame: 4 months
Urine MCP-1/Cr level
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.